Bausch + Lomb to acquire Xiidra and other ophthalmology assets from Novartis for $1.75B

Bausch + Lomb Ireland Limited, a subsidiary of Bausch + Lomb Corporation, has agreed to acquire Xiidra and other ophthalmology assets from Novartis for $1.75 billion in cash at closing, plus up to $750 million in milestone payments. The transaction is expected to close by end of 2023.

“On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation entered into a Stock and Asset Purchase Agreement with Novartis Pharma AG, Novartis Finance Corporation.”secwatch.observer

• 1 source
• secwatch.observerBLCO 8-K: Bausch + Lomb to acquire Xiidra and other ophthalmology assets from Novartis for $1.75B cash plus milestones — secwatch.observerJul 7, 2023

Summarized from public sources; check the original articles before acting on it.